CRISPR/Cas9 enables the creation of genetically modified models (in vivo and in vitro) to target key AD mechanisms, such as Aβ plaque deposition, Tau hyperphosphorylation, and neuroinflammation. This evidence concerns the gene MAPT and Alzheimer disease.